| Breast cancer is the most common malignant tumor in women and the leading cause of cancer-related deaths worldwide. In recent years, antibody drug conjugate (ADC), as a new type of antitumor drug, has shown good efficacy and safety in breast cancer treatment. With the increasingly widespread clinical application, the drug resistance problem of ADCs has received more and more attention. In this paper, we review the characteristics of ADCs, drug resistance mechanisms and their response strategies, which will provide ideas for the subsequent clinical development of therapeutic regimens to further improve the efficacy of ADCs in breast cancer and increase the benefits for patients. |
